{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:01Z","timestamp":1793159101644,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jfma.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:44:56Z","timestamp":1728567896000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of technetium-99m-pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-7442","authenticated-orcid":false,"given":"Yi-Hsin","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-5117","authenticated-orcid":false,"given":"Cheng-Hsuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6699-2298","authenticated-orcid":false,"given":"Mao-Yuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tung","family":"Shun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Wen","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4767-7636","authenticated-orcid":false,"given":"Jimmy","family":"Jyh-Ming Juang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Huei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hua","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Tsang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-0606","authenticated-orcid":false,"given":"Mei-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jfma.2024.10.005_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jfma.2024.10.005_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/acn3.51635","article-title":"Cardiomyopathy correlates to nerve damage in p.A117S late-onset transthyretin amyloid polyneuropathy","volume":"9","author":"Lin","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jfma.2024.10.005_bib5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jfma.2024.10.005_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2024.10.005_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jfma.2024.10.005_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cardfail.2022.10.013","article-title":"Primary results from apollo-B, A phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy","volume":"29","author":"Maurer","year":"2023","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.jfma.2024.10.005_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ejhf.2783","article-title":"Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study","volume":"25","author":"Rosenblum","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"17","key":"10.1016\/j.jfma.2024.10.005_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2024.10.005_bib13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA cardiology"},{"issue":"2","key":"10.1016\/j.jfma.2024.10.005_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin\u2010mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia\u2010Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jfma.2024.10.005_bib15","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jfma.2024.10.005_bib16","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jfma.2024.10.005_bib17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jfma.2024.10.005_bib18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/clc.23882","article-title":"Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia","volume":"45","author":"Lin","year":"2022","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.jfma.2024.10.005_bib19","first-page":"221","article-title":"2021 advocacy statements for the role of 99mTc-pyrophosphate scintigraphy in the diagnosis of transthyretin cardiac amyloidosis: a report of the taiwan society of cardiology and the society of nuclear medicine of the Republic of China","volume":"37","author":"Huang","year":"2021","journal-title":"Acta Cardiol Sin"},{"issue":"8","key":"10.1016\/j.jfma.2024.10.005_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"European Heart Journal-Cardiovascular Imaging"},{"issue":"2","key":"10.1016\/j.jfma.2024.10.005_bib21","first-page":"216","article-title":"A novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report","volume":"25","author":"Doumas","year":"2022","journal-title":"Hellenic J Nucl Med"},{"issue":"8","key":"10.1016\/j.jfma.2024.10.005_bib22","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11604-023-01403-4","article-title":"Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis","volume":"41","author":"Lee","year":"2023","journal-title":"Jpn J Radiol"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10.1016\/j.jfma.2024.10.005_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of technetium\u201099m\u2010pyrophosphate single\u2010photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy","volume":"13","author":"Yu","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jfma.2024.10.005_bib25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases (99m)Tc-pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jfma.2024.10.005_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52158","article-title":"Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis","author":"Chao","year":"2024","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"4","key":"10.1016\/j.jfma.2024.10.005_bib27","first-page":"511","article-title":"Expert consensus of the taiwan society of cardiology on the diagnosis and treatment of cardiac amyloidosis","volume":"39","author":"Wang","year":"2023","journal-title":"Acta Cardiol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2024.10.005_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jfma.2024.10.005_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.jfma.2024.10.005_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jfma.2024.10.005_bib31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jfma.2024.10.005_bib32","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jfma.2024.10.005_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nmd.2018.11.002","article-title":"6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR)","volume":"29","author":"Vita","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jfma.2024.10.005_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2024.100356","article-title":"Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy - a study of natural history of treatment response","volume":"26","author":"Patel","year":"2024","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.jfma.2024.10.005_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12350-013-9800-5","article-title":"Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques","volume":"21","author":"AlJaroudi","year":"2014","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10.1016\/j.jfma.2024.10.005_bib36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-023-06459-y","article-title":"Cardiac [(99m)Tc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?","volume":"51","author":"Tingen","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.jfma.2024.10.005_bib37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/acn3.778","article-title":"Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan","volume":"6","author":"Chao","year":"2019","journal-title":"Annals of clinical and translational neurology"},{"issue":"3","key":"10.1016\/j.jfma.2024.10.005_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jfma.2019.08.027","article-title":"Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser","volume":"119","author":"Lai","year":"2020","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T14:02:38Z","timestamp":1743429758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624004819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0929664624004819"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.10.005","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of technetium-99m-pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}